BridgeMD
New treatment option for Aortic Stenosis
Official title Angiotensin Receptor Blockers in Aortic Stenosis
ClinicalTrials.gov ID: NCT04913870
What this study is testing
What is Angiotensin Receptor Blockers?
Angiotensin Receptor Blockers is an investigational medicine, being studied as a potential treatment for aortic stenosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 99
You may be able to join if
- Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \<4m/s)
- Normal left ventricular ejection fraction (i.e. ≥50%)
- Systolic blood pressure \>110 mmHg
- Diastolic blood pressure \>70 mmHg
You likely can't join if
- More than mild aortic or mitral regurgitation, or mitral stenosis
- Current use or documented indication for renin-angiotensin system medication or Aliskiren
- Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
- Alzheimer, dementia or known non-compliant patient
- Renal dysfunction (glomerular filtration rate \<30ml/min/1.73m2)
- Chronic hyperkalemia
See the full eligibility criteria
- Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \<4m/s)
- Normal left ventricular ejection fraction (i.e. ≥50%)
- Systolic blood pressure \>110 mmHg
- Diastolic blood pressure \>70 mmHg
- More than mild aortic or mitral regurgitation, or mitral stenosis
- Current use or documented indication for renin-angiotensin system medication or Aliskiren
- Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
- Alzheimer, dementia or known non-compliant patient
- Renal dysfunction (glomerular filtration rate \<30ml/min/1.73m2)
- Chronic hyperkalemia
- Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
- Newly diagnosed (\<2 months) or poorly controlled diabetes
- Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (\<3 months)
- Pregnant or lactating women
- Patients unable to read, understand or sign research consent
The study team makes the final eligibility decision.
Where it's taking place
- Québec, Quebec, Canada
- Odense, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Québec, Quebec, Canada; Odense, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.